Finni Health vs Altria

Side-by-side comparison of AI visibility scores, market position, and capabilities

Altria leads in AI visibility (90 vs 32)

Finni Health

EmergingHealthcare

General

ABA therapy practice management platform with instant insurance credentialing and billing; $3.32M from General Catalyst and YC with 50% MoM growth competing with CentralReach.

AI VisibilityBeta
Overall Score
D32
Category Rank
#684 of 1167
AI Consensus
65%
Trend
stable
Per Platform
ChatGPT
28
Perplexity
42
Gemini
33

About

Finni Health is a healthcare technology platform providing business infrastructure for autism therapy providers — offering instant insurance credentialing, patient data management, billing automation, and payment processing that allows ABA (Applied Behavior Analysis) therapy practices to launch and scale without the administrative overhead that typically requires a full billing and operations team. Founded in 2023 and backed by $3.32 million led by General Catalyst and Y Combinator, Finni Health serves providers across five states and achieved $30,000 in monthly revenue with 50% month-over-month growth within seven months of launch.

Full profile

Altria

LeaderConsumer Goods

Enterprise

Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.

AI VisibilityBeta
Overall Score
A90
Category Rank
#83 of 290
AI Consensus
58%
Trend
stable
Per Platform
ChatGPT
84
Perplexity
97
Gemini
99

About

Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.

Full profile

AI Visibility Head-to-Head

32
Overall Score
90
#684
Category Rank
#83
65
AI Consensus
58
stable
Trend
stable
28
ChatGPT
84
42
Perplexity
97
33
Gemini
99
41
Claude
86
35
Grok
87

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.